Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes

Aso, Yoshimasa; Hara, Kenji; Ozeki, Noriyuki; Yatsuka, Chikako; Nakano, Takashi; Matsumoto, Sachiko; Suetsugu, Mariko; Nakamachi, Takafumi; Takebayashi, Kohzo; Haruki, Kohsuke; Iwamoto, Toshihiko

doi:10.1016/j.diabres.2009.05.015

Cited by 25 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study also demonstrated that pioglitazone is superior in increasing the level of serum adiponectin especially HMW adiponectin. A similar effect of pioglitazone on the serum HMW adiopnectin level has already been reported by Aso et al who demonstrated that low-dose pioglitazone significantly increased HMW adiponectin and improved glycemic control in patients with advanced T2DM [18]. It is now apparent that adiponectin exerts diverse effects on glucose and lipid metabolism, thereby improving insulin sensitivity and lowering TGs [19].…”

Section: Discussionsupporting

confidence: 69%

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome

Fujitaka

Otani

et al. 2011

Endocr J

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is characterized by accumulation of visceral fat associated with the clustering of metabolic and pathophysiological cardiovascular risk factors; impaired glucose tolerance or type-2 diabetes mellitus (T2DM), dyslipidemia and hypertension [1], and has a strong impact on the global incidence of the life-threatening cardiovascular disease such as stroke and myocardial infarction [2,3]. The prevalence of MetS is rapidly increasing worldwide not only in industrialized countries but also in developing countries associated with a change in the lifestyle including the increase in food intake and the decrease abstract. Type 2 diabetes mellitus (T2DM) associated with metabolic syndrome (MetS) represents a high risk of cardiovascular disease. We compared the effect of early intervention with pioglitazone versus voglibose on physical and metabolic profiles and serum adiponectin level in patients with T2DM associated with MetS. Sixty patients who were diagnosed for the first time as T2DM associated with MetS were analyzed for insulin sensitivity, lipid profile, serum adiponectin and systemic inflammation. Those patients were randomly assigned to oral pioglitazone group (n = 30) or voglibose group (n = 30) in addition to conventional diet and exercise training. Body mass index and waist circumference did not change in the pioglitazone group, whereas these physical parameters significantly decreased in the voglibose group during a 6-month follow-up period. However, glycosylated hemoglobin, fasting plasma glucose, and HOMA-IR more significantly decreased in the pioglitazone group. The level of serum adiponectin especially high-molecular weight adiponectin markedly increased in the pioglitazone group. Moreover, high sensitive CRP significantly decreased only in the pioglitazone group. These results suggest that voglibose is superior in improving obesity, while pioglitazone is superior in ameliorating insulin sensitivity and increasing serum adiponectin in patients with an early stage of T2DM associated with MetS.

show abstract

Section: Discussionsupporting

confidence: 69%

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome

Fujitaka

Otani

et al. 2011

Endocr J

View full text Add to dashboard Cite

show abstract

“…Recently, TZDs were demonstrated to have an effect on the serum levels of different adipokines such as leptin, resistin, adiponectin, and visfatin [12][13][14][15]. Chemerin is a newly discovered adipokine.…”

Section: Introductionmentioning

confidence: 99%

Rosiglitazone Ameliorates Diabetic Nephropathy by Reducing the Expression of Chemerin and ChemR23 in the Kidney of Streptozotocin-Induced Diabetic Rats

Qin

Zhang

et al. 2012

Inflammation

View full text Add to dashboard Cite

Chemerin is shown to be associated with inflammation which is involved in the pathogenesis of diabetic nephropathy. This study aims to determine whether rosiglitazone and pioglitazone ameliorate renal function through an effect on the expression of chemerin and ChemR23 in streptozotocin-induced diabetic rats. The rats were randomized to control, diabetic, rosiglitazone-, and pioglitazone-treated groups. The expression level of chemerin and ChemR23 in the renal tissues was significantly elevated in the diabetic group compared with the control group. Rosiglitazone inhibited the overexpression of chemerin and ChemR23, while pioglitazone inhibited the overexpression of ChemR23 in the kidney of diabetic rats. In addition, chemerin expression level was positively correlated with transforming growth factor-β1, connective tissue growth factor, tumor necrosis factor-α, and intracellular cell adhesion molecule-1 expression in diabetic rats. Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of chemerin and ChemR23 in diabetic rats.

show abstract

“…High-molecular-weight adiponectin [5] was measured by chemiluminescent enzyme immunoassay (CLEIA) (reference range of 4.8 ± 3.1 g/mL for males aged 46.4 ± 10.1 years and 9.0 ± 5.3 g/mL for females aged 41.5 ± 9.8 years). Dehydroepiandrosterone sulfate (DHEA-S) was measured by CLEIA (reference range of 45 (5, 253) and 35 (7, 177) g/dL (median (2.5%, 97.5%)) for males and females aged > 71 years).…”

Section: Blood Collection and Measurementsmentioning

confidence: 99%

“…An earlier concern that pioglitazone is associated with bladder cancer has largely been allayed by subsequent evidence [2,3], leaving potentially increased risk of prostate and pancreatic cancers [3]. Taking into account the risk-benefit ratio for the use of pioglitazone in the treatment of type 2 diabetes, several studies have been undertaken to examine the efficacy and safety of low-dose pioglitazone for its optimal use [4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Effects of Low-Dose Pioglitazone on Serum Levels of Adiponectin, Dehydroepiandrosterone, Amyloid Beta Peptide, and Lipid Profile in Elderly Japanese People with Type 2 Diabetes

Aoki

2015

Advances in Endocrinology

View full text Add to dashboard Cite

This study was performed to see how pioglitazone at low doses could affect blood biomarkers related to atherosclerosis and aging. The effects of an add-on treatment with pioglitazone (15 mg for males and 7.5 mg for females) for 6 months were assessed in 24 outpatients (12 males, 12 females) with type 2 diabetes aged ≥ 70 years. As doses of sulfonylurea were reduced in 10 patients, no significant differences in HbA1c and glucose levels were seen. After the treatment, serum levels of HDL cholesterol, arachidonic acid (predominant in males), and high-molecular-weight adiponectin significantly increased. The level of dehydroepiandrosterone sulfate significantly decreased. No significant changes were seen in those of small dense LDL cholesterol, high-sensitivity C-reactive protein, and amyloid beta peptides 1-40 and 1-42. There was a slight but significant increase in body weight, but apparent adverse effects were not observed. In conclusion, pioglitazone at low doses increased serum adiponectin, HDL cholesterol, and arachidonic acid levels but decreased serum dehydroepiandrosterone level, not associated with glycemia, in elderly Japanese people with type 2 diabetes. An optimal dose of pioglitazone should be sought for to minimize its adverse effects and to fully exert its pleiotropic effects such as antiatherosclerotic and antiaging effects.

show abstract

Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes

Cited by 25 publications

References 25 publications

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome

Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome

Rosiglitazone Ameliorates Diabetic Nephropathy by Reducing the Expression of Chemerin and ChemR23 in the Kidney of Streptozotocin-Induced Diabetic Rats

Effects of Low-Dose Pioglitazone on Serum Levels of Adiponectin, Dehydroepiandrosterone, Amyloid Beta Peptide, and Lipid Profile in Elderly Japanese People with Type 2 Diabetes

Contact Info

Product

Resources

About